← Back to all trials
Recruiting
NCT07572825
Assessing the Safety and Tolerability of NMN in DHDDS-CDG
Conditions: DHDDS-Congenital Disorder of Glycosylation, DHDDS-CDG, Congenital Disorder of Glycosylation
Sex: All
Ages: 4 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 8
Sponsor: Eva Morava-Kozicz
Location: Icahn School of Medicine at Mount Sinai New York New York
Summary
The primary objective of this study is to evaluate the safety and tolerability of the dietary supplement, nicotinamide mononucleotide (NMN), in individuals with dehydrodolichol diphosphate synthase congenital disorder of glycosylation (DHDDS-CDG). This will to contribute to knowledge that will allow healthcare providers to make informed decisions about recommending this dietary supplement in this population.
Eligibility Criteria
Inclusion Criteria:
* Subject is ≥ 4 years old
* Subject has biologically and genetically proven heterozygous DHDDS-CDG.
* Subject/legally authorized representative (LAR) is able to understand and provide written informed consent, and assent (as applicable) to participate in this study.
Exclusion Criteria:
* Subject has intellectual disability with IQ\
Source: ClinicalTrials.gov (NCT07572825). StuddyBuddy aggregates publicly available trial information.
